Executive Director, Chemical Engineering Lead
Madrigal Pharmaceuticals
Summary
Leads chemical engineering strategy and execution oversight to ensure DS/DP processes are scalable, safe, and transferable to external manufacturing. Defines equipment/process suitability expectations, drives process safety and manufacturability assessments, and supports resolution of scale-up constraints. Ensures engineering inputs align with validation strategy and sustained performance post-transfer, enabling reliable supply execution.
Job description
Key Responsibilities
- Set engineering standards for scale-up readiness, safety, and process/equipment fit
- Support DS/DP teams in defining scalable process parameters and operating ranges
- Lead engineering input to tech transfer, process safety reviews, and risk assessments
- Drive yield/throughput/cycle-time improvement opportunities with external partners
- Ensure engineering documentation supports validation readiness and audit expectations
Required Qualifications
- BS+ in Chemical Engineering (advanced degree preferred)
- 18+ years in process/chemical engineering supporting GMP manufacturing/tech transfer
- Demonstrated leadership in scale-up, safety, and external manufacturing collaboration
- Strong cross-functional influence and structured problem solving
Preferred Qualifications
- Experience supporting SDD process scale-up and solvent/safety considerations
- Experience supporting validation/PPQ readiness activities
Key Competencies
- Scale-up engineering, process safety, and manufacturability
- Tech transfer readiness and constraint resolution
- Continuous improvement and performance-focused execution
- Documentation rigor and stakeholder communication
Requirements
- BS+ in Chemical Engineering (advanced degree preferred)
- 18+ years in process/chemical engineering supporting GMP manufacturing/tech transfer
- Demonstrated leadership in scale-up, safety, and external manufacturing collaboration
- Strong cross-functional influence and structured problem solving
- Experience supporting SDD process scale-up and solvent/safety considerations
- Experience supporting validation/PPQ readiness activities
Benefits
- Health Insurance
- Dental Insurance
- Vision Insurance
- Life Insurance
- Disability Insurance
- 401(k) Matching
- Equity
- Bonus
- Flexible PTO
- Mental Health Benefits
- Employee Assistance Program
- Supplemental Life Insurance
- Legal Services
Company overview
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. The company's lead product, Rezdiffra (resmetirom), is a once-daily, oral thyroid hormone receptor (THR)-β selective agonist that targets key underlying causes of MASH in the liver. Rezdiffra received FDA approval in 2024 as the first treatment for MASH with moderate to advanced liver fibrosis, representing a significant breakthrough in hepatology. Headquartered in Conshohocken, Pennsylvania, Madrigal is publicly traded on NASDAQ under the symbol MDGL. The company continues to advance its clinical development programs, including ongoing Phase 3 trials evaluating Rezdiffra for the treatment of compensated MASH cirrhosis. Madrigal's innovative approach addresses a critical unmet medical need in liver disease therapeutics.